Report Company Directory

QUALCOMM INCORPORATED

• Focus: Quantamental Credit Quarterly: November 2024 by Barclays
• US Credit Alpha: Few obstacles remain by Barclays
• QPS & Credit Research: Quantamental Credit Quarterly: November 2024 by Barclays
• US Credit Research & Strategy: 2Q23 Corporate Earnings Scorecard: July 31-Aug 4 by Barclays
• US Credit Research & Strategy: 1Q23 Corporate Earnings Scorecard: Week of May 5 by Barclays
• US HG Research: QCOM/AAPL: QCOM 4Q Weak on Smartphones; Downgrading Apple to UW by Barclays

Quali-Smart Holdings

• Quali-Smart Holdings Ltd: 1 director bought by SmartInsider
• Ford Equity International Rating and Forecast Report by Ford Equity Research

Qualicorp Consultoria e Corretora de Seguros S.A.

• Itaú BBA on Healthcare: Pulse Check #44 - Sequential Improvement on HAPV, Despite NDI Still Down; a Solid QTD for Amil, SulAmérica and Bradesco by Itau
• Itaú BBA on Healthcare: Pulse Check #43 - HAPV Reports -28k for the Month; SULA Continues to Advance with +78k MoM by Itau
• Itaú BBA on Brazil Equity Strategy: IBBA Quantitative (IQ) Series – Monthly Tracker: Our Update of Proprietary Factor Portfolios. IQM and IQPM are the Highlights by Itau
• Itaú BBA on Qualicorp: Soft but Expected Results with Portfolio Contraction by Itau
• Itaú BBA on Healthcare: Proposed Regulatory Changes Update: Detailed Review of Technical Notes by Itau
• Itaú BBA on Healthcare: 1Q25 Earnings Preview by Itau
• Itaú BBA on Healthcare: Pulse Check #41 - HAPV Loses 90k YTD; OK Print for SULA by Itau
• Itaú BBA on Qualicorp: Better Top-Line Trends Despite a Lackluster Profitability by Itau
• Itaú BBA on Healthcare: Pulse Check #37 - Industry Decelerates; HAPV and SULA Lose Beneficiaries in the Month by Itau
• Itaú BBA on Qualicorp: Healthy FCF and Lower Churn YoY; Still Waiting for a Rebound in Gross Adds by Itau

QUALIFIED INVESTOR SICAV

Qualigen Therapeutics Inc

• Qualigen Granted New Patents Covering 25 Countries by GlobeNewsWire
• Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q by GlobeNewsWire
• Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K by GlobeNewsWire
• Qualigen seeks to enter the $10 Billion CABG market with non-binding MOU to acquire Marizyme by GlobeNewsWire
• Qualigen to participate in next funding round for NanoSynex by GlobeNewsWire
• Qualigen Therapeutics Announces Regained Compliance with Nasdaq's Minimum Bid Price Requirement and the Equity Requirement by GlobeNewsWire
• Qualigen Therapeutics Announces $4.5 Million Private Placement of Convertible Preferred Shares by GlobeNewsWire
• Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024 by GlobeNewsWire
• Qualigen Therapeutics, Inc. Announces management changes. by GlobeNewsWire
• Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel by GlobeNewsWire